The estimated Net Worth of Richard J. Tajak is at least $483 Tausend dollars as of 23 March 2017. Richard Tajak owns over 5,000 units of NantKwest Inc stock worth over $482,769 and over the last 9 years Richard sold NK stock worth over $0.
Richard has made over 4 trades of the NantKwest Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Richard exercised 5,000 units of NK stock worth $162,450 on 23 March 2017.
The largest trade Richard's ever made was exercising 5,000 units of NantKwest Inc stock on 23 March 2017 worth over $162,450. On average, Richard trades about 4,000 units every 55 days since 2016. As of 23 March 2017 Richard still owns at least 14,859 units of NantKwest Inc stock.
You can see the complete history of Richard Tajak stock trades at the bottom of the page.
Richard's mailing address filed with the SEC is C/O NANTKWEST, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121.
Over the last 9 years, insiders at NantKwest Inc have traded over $20,345,739 worth of NantKwest Inc stock and bought 4,163,265 units worth $55,365,252 . The most active insiders traders include Patrick Cambridge Equities,..., Steve Gorlin und Barry J. Simon. On average, NantKwest Inc executives and independent directors trade stock every 33 days with the average trade being worth of $5,362,832. The most recent stock trade was executed by Richard Adcock on 5 February 2021, trading 150,000 units of NK stock currently worth $4,873,500.
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
NantKwest Inc executives and other stock owners filed with the SEC include: